The efficacy of adjuvant targeted therapy in ALK fusion and EGFR mutation NSCLC has been demonstrated, while the effectiveness of perioperative targeted therapy for BRAF V600E NSCLC remains uncertain. Here, ALK is linked to non-small cell lung carcinoma.